{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:18:26Z","timestamp":1758637106459},"reference-count":53,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011949","name":"Abbott Vascular","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.pcad.2018.01.006","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T12:13:39Z","timestamp":1517573619000},"page":"491-499","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Duration of Dual Antiplatelet Therapy for Stented Patients: An Update for the Clinician"],"prefix":"10.1016","volume":"60","author":[{"given":"Mahesh K.","family":"Vidula","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Secemsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.pcad.2018.01.006_bb0005","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2018.01.006_bb0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.pcad.2018.01.006_bb0015","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.pcad.2018.01.006_bb0020","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jacc.2016.03.512","volume":"68","author":"Bittl","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.pcad.2018.01.006_bb0025","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (real safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.pcad.2018.01.006_bb0030","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.pcad.2018.01.006_bb0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of Xience\/Promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.pcad.2018.01.006_bb0040","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second- generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.pcad.2018.01.006_bb0045","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo- controlled trial of 6 vs. 12\u202fmonths of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Sch\u00fcpke","year":"2015","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.pcad.2018.01.006_bb0050","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-month versus 12-month dual- antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial","volume":"9","author":"Hong","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"8","key":"10.1016\/j.pcad.2018.01.006_bb0055","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.pcad.2018.01.006_bb0060","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.pcad.2018.01.006_bb0065","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurheartj\/ehs460","article-title":"Should duration of dual antiplatelet therapy depend on the type and\/or potency of implanted stent? A pre-specified analysis from the PROlonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia studY (PRODIGY)","volume":"34","author":"Valgimigli","year":"2013","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.pcad.2018.01.006_bb0070","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jacc.2014.12.046","article-title":"Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis","volume":"65","author":"Palmerini","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2018.01.006_bb0075","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pcad.2018.01.006_bb0080","first-page":"365","article-title":"Stopping or continuing clopidogrel 12\u202fmonths after drug-eluting stent placement: the OPTIDUAL randomized trial","volume":"37","author":"Helft","year":"2016","journal-title":"Eur Heart J"},{"issue":"9954","key":"10.1016\/j.pcad.2018.01.006_bb0085","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.pcad.2018.01.006_bb0090","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pcad.2018.01.006_bb0095","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamacardio.2017.0063","article-title":"Mortality following cardiovascular and bleeding events occurring beyond 1 year after coronary stenting a secondary analysis of the dual antiplatelet therapy (DAPT) study","volume":"2","author":"Secemsky","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"9985","key":"10.1016\/j.pcad.2018.01.006_bb0100","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.pcad.2018.01.006_bb0105","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.jacc.2017.02.029","article-title":"Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting","volume":"69","author":"Palmerini","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"9970","key":"10.1016\/j.pcad.2018.01.006_bb0110","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0140-6736(14)62052-3","article-title":"Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis","volume":"385","author":"Elmariah","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2018.01.006_bb0115","author":"US Food and Drug Administration (FDA)"},{"issue":"4","key":"10.1016\/j.pcad.2018.01.006_bb0120","first-page":"390","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials","volume":"37","author":"Udell","year":"2016","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.pcad.2018.01.006_bb0125","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jacc.2017.09.011","article-title":"Lesion complexity and outcomes of extended dual antiplatelet therapy after percutaneous coronary intervention","volume":"70","author":"Yeh","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.pcad.2018.01.006_bb0130","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and safety of dual antiplatelet therapy after complex PCI","volume":"68","author":"Giustino","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.pcad.2018.01.006_bb0135","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.pcad.2018.01.006_bb0140","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.pcad.2018.01.006_bb0145","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.pcad.2018.01.006_bb0150","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.006_bb0155","article-title":"Six versus twelve months of dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction","author":"Kumbhani","year":"2017","journal-title":"Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.pcad.2018.01.006_bb0160","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond one year after percutaneous coronary intervention: an analysis from the randomized dual antiplatelet therapy study","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pcad.2018.01.006_bb0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7326\/M16-2389","article-title":"Use of the dual-antiplatelet therapy score to guide treatment duration after percutaneous coronary intervention","volume":"167","author":"Piccolo","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcad.2018.01.006_bb0170","article-title":"Validating utility of DAPT score in a large pooled cohort from three Japanese PCI studies","author":"Yoshikawa","year":"2017","journal-title":"Circulation"},{"issue":"10073","key":"10.1016\/j.pcad.2018.01.006_bb0175","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.pcad.2018.01.006_bb0180","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9872","key":"10.1016\/j.pcad.2018.01.006_bb0185","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.pcad.2018.01.006_bb0190","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.pcad.2018.01.006_bb0195","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.pcad.2018.01.006_bb0200","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pcad.2018.01.006_bb0205","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.pcad.2018.01.006_bb0210","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.pcad.2018.01.006_bb0215","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.pcad.2018.01.006_bb0220","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.jacc.2015.04.017","article-title":"Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis","volume":"65","author":"Palmerini","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"9824","key":"10.1016\/j.pcad.2018.01.006_bb0225","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(12)60324-9","article-title":"Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis","volume":"379","author":"Palmerini","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pcad.2018.01.006_bb0230","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jacc.2013.05.022","article-title":"Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis","volume":"62","author":"Palmerini","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"10115","key":"10.1016\/j.pcad.2018.01.006_bb0235","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial","volume":"391","author":"Varenne","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.pcad.2018.01.006_bb0240","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jcin.2017.04.019","article-title":"Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation","volume":"10","author":"Nakamura","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.pcad.2018.01.006_bb0245","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003145","article-title":"Six versus 12\u202fmonths of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial","volume":"9","author":"Han","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"23","key":"10.1016\/j.pcad.2018.01.006_bb0250","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.jacc.2017.10.010","article-title":"3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: The ABSORB III trial","volume":"70","author":"Kereiakes","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.pcad.2018.01.006_bb0255","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4244\/EIJY15M11_07","article-title":"Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus- eluting stent implantation: rationale and design of the GLOBAL LEADERS trial","volume":"12","author":"Vranckx","year":"2016","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2018.01.006_bb0260","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ahj.2016.09.006","article-title":"Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study","volume":"182","author":"Baber","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2018.01.006_bb0265","author":"US National Library of Medicine"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062018300239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062018300239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T18:44:58Z","timestamp":1656096298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062018300239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":53,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0033062018300239"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2018.01.006","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of Dual Antiplatelet Therapy for Stented Patients: An Update for the Clinician","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2018.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}